Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duke Energy Corp (DUK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Duke Energy CorpTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Duke Energy Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Duke Energy Corp trades at $123.5 (market cap $96.05B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Duke Energy Corp pays a 3.52% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Duke Energy Corp nearer its low. Which is the better fit depends on your goals.

DUKXBI
Market Cap
$96.05B
Sector
UtilitiesBroad Market / Factor
52-Week High
$133.46$164.28
52-Week Low
$113.99$86.92
Enterprise Value
$188.56B
Dividend Yield
3.52%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duke Energy Corp

Duke Energy (DUK) trades at $123.23, up 1.68% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.43 exceeding expectations, supported by growing revenue and healthy profit margins. Recent news highlights operational challenges from storms affecting customers but also strategic initiatives including a $35 million equity units offering and data center growth opportunities.

The outlook remains stable with analyst consensus pointing to upside potential (target $136.17) and no sell ratings. Key risks include regulatory scrutiny and capital expenditure pressures, but the company's dividend reliability and infrastructure investments provide long-term stability. The stock presents a balanced opportunity for income-focused investors amid current technical weakness.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.

Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Duke Energy Corp

Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure

Read more on DUK

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI